|
Radiation Therapy Following Surgery to Remove Brain Metastases Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Radiation Therapy Following Surgery to Remove Brain Metastases conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Radiation Therapy Following Surgery to Remove Brain Metastases Clinical research trials and Radiation Therapy Following Surgery to Remove Brain Metastases health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Radiation Therapy Following Surgery to Remove Brain Metastases. Radiation Therapy Following Surgery to Remove Brain Metastases Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Radiation Therapy Following Surgery to Remove Brain Metastases clinical trial. Human subjects often get the best healthcare possible for their Radiation Therapy Following Surgery to Remove Brain Metastases condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiation Therapy Following Surgery to Remove Brain Metastases  Radiation Therapy Following Surgery to Remove Brain Metastases
Radiation Therapy Following Surgery to Remove Brain Metastases
For Condition: Brain Neoplasms,Metastasis
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery to remove brain metastases may decrease the amount of radiation required to treat brain metastases. PURPOSE: Pilot trial to study the effectiveness of radiation therapy following surgery to remove brain metastases.
Details: OBJECTIVES: I. Assess the safety and tolerability of focal stereotactic radiotherapy to the surgical bed following excision of cerebral metastases, as an alternative to whole brain irradiation. II. Measure the local relapse rate at the surgical site after surgery and stereotactic radiotherapy in patients with cerebral metastases. III. Measure the regional relapse rate, in the brain but away from the treated site, following treatment in these patients. PROTOCOL OUTLINE: All patients undergo surgical removal of their cerebral metastases followed by adjuvant fractionated stereotactic radiotherapy daily for 5 days. Patients are given up to 5 weeks following surgery to recover and reach the required performance status. Radiotherapy must commence within 6 weeks of surgery. Patients are followed at 2 weeks after treatment, monthly for 6 months, every 3 months for the next 18 months, every 6 months for the next year, and then annually for years 3-5. PROJECTED ACCRUAL: There will be 20-40 patients accrued into this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed cerebral metastases post surgical resection; No greater than 3 cerebral metastases postresection - Gross resection at operation as documented in operation note and postoperative MRI - Patients must have current surgical sites that have not been previously irradiated - No other indication for whole brain irradiation (i.e., multiple untreated metastases not suitable for single fraction stereotactic radiotherapy, leptomeningeal disease) --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No concurrent chemotherapy - Endocrine therapy: Prior or concurrent required steroids allowed - Radiotherapy: No prior whole brain irradiation or focal irradiation to current sites of disease; Prior stereotactic radiotherapy of cerebral metastases allowed provided no prior irradiation of current surgical sites - Surgery: Prior surgery of cerebral metastases allowed --Patient Characteristics-- - Age: 18 and over - Performance status: Karnofsky 60-100% - Life expectancy: At least 3 months - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Pulmonary: No severe asthma requiring therapy - Other: No allergy to iodine or contrast media; Not pregnant
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JudithFord, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000066270; UCLA-HSPC-970101503,NCI-G98-1416,UCLA-HSPC-970101502
Study Start Date: March 1997
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003320
Other Metastasis Studies:
1. An investigational drug (CAL) versus zoledronic acid (Zometa®) in patients with breast cancer
2. Radiation Therapy Following Surgery to Remove Brain Metastases
Related Studies:
Other Metastasis Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Radiation Therapy Following Surgery to Remove Brain Metastases
|
|
|
|
|
|
|
|
